Study Objectives: To characterize the nature and impact of sleep disturbances on quality of life (QOL) in women with interstitial cystitis/bladder pain syndrome (IC/BPS). Methods: Participants were 3,397 women from a telephone probability survey who met IC/BPS symptom criteria. Sleep quality, duration, and IC/BPS nocturnal symptoms (i.e., trouble sleeping due to bladder pain, urgency, or needing to use the bathroom), general QOL (mental and physical health and sexual functioning), and IC/BPS QOL impairment were assessed via self-report during telephone interview. Results: Over half of the sample reported poor sleep quality, sleep duration ≤ 6 hours, or trouble sleeping due to IC/BPS symptoms. After covariate adjustment, short sleep duration was signifi cantly associated with greater IC/BPS QOL impairment (β = -0.04; p < 0.001) and poorer self-reported physical health (β = 1.86; p < 0.001). Poor sleep quality was signifi cantly associated with greater IC/BPS QOL impairment (β = 0.06; p < 0.001), poorer self-reported physical health (β = -2.86; p < 0.001), and greater sexual dysfunction (β = -0.04; p < 0.05).IC/BPS nocturnal symptoms were signifi cantly associated with greater IC/BPS impairment (β = 0.14; p < 0.001), poorer physical health (β = -2.76; p < 0.001) and mental health (β = 0.52; p < 0.01), and greater sexual dysfunction (β = -0.10; p < 0.001), after covariate adjustment. After further adjustment for IC/BPS nocturnal symptoms, we found that poor sleep quality and short sleep duration were independent correlates of poor self-reported physical health. Conclusions: Poor sleep quality and short sleep duration, as well as disorder-specifi c sleep disturbances, are highly prevalent in women with IC/BPS and are associated with poorer disease-specifi c and general QOL.
S C I E N T I F I C I N V E S T I G A T I O N SI nterstitial cystitis (IC)/ bladder pain syndrome (BPS) is a chronic pain syndrome which disproportionately affects women and is characterized by symptoms of urinary urgency and frequency, pelvic pain, and nocturia.1 The etiology and pathophysiology of IC/BPS are currently unknown; however, prevailing theories implicate chronic or subclinical infection, autoimmunity, neurogenic infl ammation, or bladder urothelial defects (i.e., epithelial lining of the urinary tract) as potential mechanisms.
2In the absence of known or measurable pathophysiological biomarkers, the clinical diagnosis of IC/BPS is based on patient-reported symptoms, and many cases remain undiagnosed. For instance, in the RAND Interstitial Cystitis Epidemiology (RICE) Study (from which the current data are drawn), a nationally representative population survey, up to 6.5% of US women reported experiencing IC/BPS symptoms according to established case criteria, but less than 10% of these women had an IC/BPS diagnosis.3 Adding to the diagnostic uncertainty is the considerable symptom overlap and comorbidity between IC/BPS and other chronic pain conditions, such as fi bromyalgia, chronic fatigue syndrome, and irritable bowel syndrome (IB...